Kura joins the pivotal menin push
The menin inhibitor battle shapes up with Kura, Syndax and J&J all now in phase 3.
Vor looks to answer the Car-T question
Can the company add a Car-T string to its stem cell transplant bow?
J&J catches its menin rivals
The company has caught up with Syndax and overtaken Kura in the first-line menin inhibitor race.
Kyowa joins GSK in Tim-3
Meanwhile, Tango tries again in PRMT5.
Kura’s Komet fizzles
The company heralds a pivotal win with its menin inhibitor, but investors want to see data.
AstraZeneca doubles down on GPC3
The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.
